Podcasts

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, talks about the effects of COVID on worldwide biomanufacturing, and what the repatriation of pharma could look like.

Scott Nawrocki, managing director of digital investigations and cyber defense at Nardello & Co., discusses cybersecurity in pharma, including topics from prevention to crisis management.

Editorial Director, Lisa Henderson; European and online editor, Julian Upton; Senior Editor, Elaine Quilici ;and Assistant Editors of Pharmaceutical Executive, Miranda Schmalfuhs and Andy Studna, discuss some exciting industry trends for 2021, which they recently wrote for the January issue.

Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like.

Rich Horgan, founder and president of Cure Rare Disease (CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.

Sacha Ward, chief client officer of Point of Care Network, discusses how COVID has affected the roles of nurse practitioners and physician assistants, and why marketing managers should take a moment to understand this growing group of health care influencers.

Krystle Buntemeyer, president of SCORR Marketing, and Bharat Mehta, co-founder of PharmaCompass, discuss a new, free online tool called Pipeline Prospector, which they recently launched in collaboration.

Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.

Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.

George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.

Jack Khattar, president and CEO of Supernus Pharmaceuticals, talks about his experience bringing ADHD drugs to market in a challenging environment.

Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times.

Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.

Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

Pharm Exec editors discuss the themes chosen for the January issue focusing on industry trends for the coming year.

Heather Monte, Director of Operations for DirectRx, talks about the specialty pharma’s new Patient Scorecard, which aims to identify and improve adherence by reporting patients’ prescription patterns to doctors.

Julia Owens, co-founder and CEO of Millendo Therapeutics talks about how to keep a company on the path to success, even when there are bumps in the road. She discusses the value of focusing on strengths and how that is currently working for Millendo in the endocrine space.

William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.

Pharm Exec editors discuss the articles they focused on for the November Annual Pipeline Report.

Sven Klingemann, research director at Reputation Institute talks about pharma’s negative public perception and what the industry can do to improve it.

Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.

Jeannine Lynch, senior director at BioMarin Pharmaceuticals, oversees patient access services and talks with editors about the patient journey in regard to receiving therapies, how to engage with patients more effectively, and where she sees the pharma industry in terms of patient engagement and patient centricity.

Janssen’s company group chairman of Europe, Middle East, and Africa operations, Kris Sterkens speaks with Pharm Exec editors. Kris talks about his finance background, global pricing issues, and challenges and opportunities for EMEA biopharma breaking into the US market.